The role of <scp>GLP</scp>‐1 receptor agonists as weight loss agents in patients with and without type 2 diabetes

Dar, Shujah; Tahrani, Abd A; Piya, Milan K.

doi:10.1002/pdi.1978

Cited by 19 publications

(18 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The chronic administration of these hormones also resulted in weight loss in animal and human models (62,(87)(88)(89) . GLP-1 analogue Liraglutide has been approved as a weight loss treatment in patients without diabetes since 2015 (90) . These highlight that GLP-1 and PYY are key regulators of appetite regulation and that their manipulation may have an effect on energy intake and body weight.…”

Section: Peripheral Control Of Appetitementioning

confidence: 99%

Understanding the interplay between food structure, intestinal bacterial fermentation and appetite control

et al. 2020

View full text Add to dashboard Cite

Epidemiological and clinical evidence highlight the benefit of dietary fibre consumption on body weight. This benefit is partly attributed to the interaction of dietary fibre with the gut microbiota. Dietary fibre possesses a complex food structure which resists digestion in the upper gut and therefore reaches the distal gut where it becomes available for bacterial fermentation. This process yields SCFA which stimulate the release of appetite-suppressing hormones glucagon-like peptide-1 and peptide YY. Food structures can further enhance the delivery of fermentable substrates to the distal gut by protecting the intracellular nutrients during upper gastrointestinal digestion. Domestic and industrial processing can disturb these food structures that act like barriers towards digestive enzymes. This leads to more digestible products that are better absorbed in the upper gut. As a result, less resistant material (fibre) and intracellular nutrients may reach the distal gut, thus reducing substrates for bacterial fermentation and its subsequent benefits on the host metabolism including appetite suppression. Understanding this link is essential for the design of diets and food products that can promote appetite suppression and act as a successful strategy towards obesity management. This article reviews the current evidence in the interplay between food structure, bacterial fermentation and appetite control.

show abstract

Section: Peripheral Control Of Appetitementioning

confidence: 99%

Understanding the interplay between food structure, intestinal bacterial fermentation and appetite control

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In patients with obesity with T2DM, glucagon-like peptide-1 receptor agonists (GLP-1 RA), like semaglutide and dulaglutide, help control hyperglycemia and reduce weight. GLP-1 RAs act on alpha cells of the pancreas to inhibit glucagon secretion, and have extra-pancreatic effects, such as increased satiety and delayed gastric emptying [ 52 ]. Thus, their impact is mainly on the gut endocrine system, and is similar to but less than that achieved by bariatric surgery.…”

Section: Endocrine Impact Of Obesity Managementmentioning

confidence: 99%

Barocrinology: The Endocrinology of Obesity from Bench to Bedside

et al. 2020

View full text Add to dashboard Cite

Obesity has reached pandemic proportions. Hormonal and metabolic imbalances are the key factors that lead to obesity. South Asian populations have a unique phenotype, peculiar dietary practices, and a high prevalence of consanguinity. Moreover, many lower middle-income countries lack appropriate resources, super-specialists, and affordability to manage this complex disorder. Of late, there has been a substantial increase in both obesity and diabesity in India. Thus, many more patients are being managed by different types of bariatric procedures today than ever before. These patients have many types of endocrine and metabolic disturbances before and after bariatric surgery. Therefore, these patients should be managed by experts who have knowledge of both bariatric surgery and endocrinology. The authors propose “Barocrinology”, a novel terminology in medical literature, to comprehensively describe the field of obesity medicine highlighting the role of knowing endocrine physiology for understating its evolution, insights into its complications and appreciating the changes in the hormonal milieu following weight loss therapies including bariatric surgery. Barocrinology, coined as a portmanteau of “baro” (weight) and endocrinology, focuses upon the endocrine and metabolic domains of weight physiology and pathology. This review summarizes the key pointers of bariatric management from an endocrine perspective.

show abstract

“…Mean weight loss has been estimated at between 0.4 and 5.1 kg. However, this improvement in weight varies between GLP-1 RAs and between individuals, although up to 30% of patients do not lose weight [ 36 ].…”

Section: Beneficial Effects Of Glp-1 Analogues On Cardiovascular Rmentioning

confidence: 99%

“…Systematic reviews and meta-analyses of GLP-1 RAs that have included studies on liraglutide (1.2 and 1.8) and exenatide (daily and weekly) have demonstrated weight loss but have been unable to show a significant difference between the agents and different doses. However, head-to-head trials seem to show that lixisenatide and albiglutide have a weaker effect on weight loss [ 36 ].…”

Section: Beneficial Effects Of Glp-1 Analogues On Cardiovascular Rmentioning

confidence: 99%

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes

García

Merino-Torres

2018

Journal of Diabetes Research

View full text Add to dashboard Cite

Diabetes mellitus is a chronic disease prevalence of which is high and continually growing. Cardiovascular disease continues to be the leading cause of death in patients with T2DM. The prevention of cardiovascular complications and the cardiovascular safety of treatments should be a primary objective when selecting treatment. Among all the drugs available, the compounds known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) appear to be not just innocuous in terms of CVD but indeed to be beneficial. GLP-1 RA actions not only translate on an improvement of well-known cardiovascular risk factors such as glycaemic control, dyslipidaemia, weight, or arterial hypertension but also might show benefits on endothelial function, coronary ischaemia, and heart failure. On the other hand, recent clinical trials aimed at studying cardiovascular episodes have been conducted with GLP-1 RAs. Only liraglutide and semaglutide have shown superiority in cardiovascular benefit compared with placebo. Although many of the mechanisms by which liraglutide and semaglutide produce a cardiovascular benefit are still unknown it would be desirable for these benefits to be incorporated into the therapeutic algorithms routinely used in clinical practice. The purpose of this review is to explore GLP-1 RA actions not only in cardiovascular risk factors (glucose, weight, and hypertension) but also the possible effects on established cardiovascular disease.

show abstract

The role of GLP‐1 receptor agonists as weight loss agents in patients with and without type 2 diabetes

Cited by 19 publications

References 60 publications

Understanding the interplay between food structure, intestinal bacterial fermentation and appetite control

Understanding the interplay between food structure, intestinal bacterial fermentation and appetite control

Barocrinology: The Endocrinology of Obesity from Bench to Bedside

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes

Contact Info

Product

Resources

About